Analyzing Amedica (AMDA) and Alliqua Biomedical (ALQA)

Amedica (NASDAQ:AMDA) and Alliqua Biomedical (NASDAQ:ALQA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.

Insider and Institutional Ownership

3.7% of Amedica shares are held by institutional investors. Comparatively, 17.7% of Alliqua Biomedical shares are held by institutional investors. 0.9% of Amedica shares are held by company insiders. Comparatively, 13.2% of Alliqua Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Amedica has a beta of -1.32, indicating that its share price is 232% less volatile than the S&P 500. Comparatively, Alliqua Biomedical has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Amedica and Alliqua Biomedical, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amedica 0 2 0 0 2.00
Alliqua Biomedical 0 1 0 0 2.00

Alliqua Biomedical has a consensus target price of $2.80, suggesting a potential upside of 30.23%. Given Alliqua Biomedical’s higher probable upside, analysts clearly believe Alliqua Biomedical is more favorable than Amedica.

Earnings & Valuation

This table compares Amedica and Alliqua Biomedical’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amedica $11.22 million 0.30 -$9.32 million N/A N/A
Alliqua Biomedical $19.57 million 0.55 -$25.70 million ($6.49) -0.33

Amedica has higher earnings, but lower revenue than Alliqua Biomedical.

Profitability

This table compares Amedica and Alliqua Biomedical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amedica -139.44% -148.66% -67.85%
Alliqua Biomedical -99.08% -169.35% -87.33%

Summary

Alliqua Biomedical beats Amedica on 7 of the 10 factors compared between the two stocks.

About Amedica

Amedica Corporation, a biomaterial company, develops, manufactures, and commercializes a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. The company offers silicon nitride implants to surgeons and hospitals for use in cervical and thoracolumbar spine surgery under the Valeo brand. It also provides a line of non-silicon nitride spinal fixation products to address spinal deformity and degenerative conditions. The company markets and sells its products directly; and through a network of independent sales distributors, as well original equipment manufacturer and private label partnerships. Amedica Corporation was founded in 1996 and is headquartered in Salt Lake City, Utah.

About Alliqua Biomedical

Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies. It also provides contract manufacturing services, including the development, manufacture, and marketing of high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Yardley, Pennsylvania.

Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply